Testing two medications together for aggressive lymphoma that didn't respond to other treatments

This trial is testing whether two medications—duvelisib and venetoclax—work better when given together to treat peripheral T-cell lymphoma that has returned or stopped responding to prior treatments. Researchers will first figure out the safest and most effective doses of these medications when combined, then test how well they actually work against this type of blood cancer. If you respond well to the treatment, you may be able to continue it beyond two years.

Peripheral T-cell lymphoma is an aggressive cancer that often comes back or becomes resistant to standard treatments, leaving patients with limited options. This trial explores whether combining two different types of medications might be more effective than either drug alone for patients whose disease has already proven difficult to treat.